• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers develop smart drugs using ‘DNA computers’ for controlled delivery

February 21, 2017 By Sarah Faulkner

Researchers develop smart drugs using 'DNA computers' for controlled deliveryResearchers from the Eindhoven University of Technology have developed the 1st “DNA computer” that can detect several antibodies in the blood and perform calculations based on what it detects. The team published their work in Nature Communications and said that it’s an important step towards developing smart drugs that allow for more targeted and controlled medication delivery.

The researchers described their DNA computer as a security system that can open a door depending on the person standing in front of it. In other words, the computer can recognize the antibodies in a person’s blood and determine whether or not to release a medication.

“Research into diagnostic tests tends to focus on the ‘recognition’, but what is special about this system is that it can think and that it can be connected to actuation such as drug delivery,” lead author Maarten Merkx said in prepared remarks.

DNA molecules, which carry genetic information, are useful for performing molecular calculations – a sequence within a DNA molecule can determine if its compatible to react with other DNA molecules. Biomedical applications of DNA computers have been limited in the past, but Merkx’s team is the 1st to use antibodies with a DNA computer.

Based on the presence of 1 or more antibodies, the molecular computer can decide whether drug delivery is necessary, the team said.

“The presence of a particular DNA molecule sets in motion a series of reactions whereby we can get the DNA computer to run various programs,” 1st author Wouter Engelen said. “Our results show that we can use the DNA computer to control the activity of enzymes, but we think it should also be possible to control the activity of a therapeutic antibody.”

Therapeutic antibodies, including the ones used to treat chronic diseases such as rheumatism and Crohn’s disease, could benefit from controlled and targeted drug delivery, according to Merkx.

“By directly linking the measurement of antibodies to the treatment of the disease, we may be able to prevent side-effects and reduce costs in the future,” Merkx said.

Filed Under: Featured, Pharmaceuticals, Research & Development Tagged With: Eindhoven University of Technology

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS